The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than ...

Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine ...

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like ...

The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly ...